Related Experiment Video

Updated: May 11, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K

PDCs: A Vital Drop in the Ocean of Funding for Pediatric Devices

Jim Banks

    IEEE Pulse
    |September 20, 2024
    PubMed

    Insights

    Pediatric Device Consortia (PDC) offer crucial funding and expertise for developing innovative medical devices for children. These organizations address unique challenges in pediatric device development, supporting original equipment manufacturers (OEMs) through regulatory guidance and successful project examples.

    Area of Science:

    • Biomedical Engineering
    • Medical Device Development
    • Pediatric Healthcare Innovation

    Background:

    • Developing medical devices for pediatric populations presents unique challenges compared to adult or general medical devices.
    • Traditional funding and development pathways often do not adequately address the specific needs of pediatric innovation.
    • The role of specialized consortia in bridging these gaps is increasingly recognized.

    Purpose of the Study:

    • To examine the function and impact of Pediatric Device Consortia (PDC) in fostering innovative pediatric medical device development.
    • To analyze the funding models and support mechanisms provided by PDCs to original equipment manufacturers (OEMs).
    • To compare the PDC model with European approaches to pediatric device funding.

    Main Methods:

    • In-depth examination of the PDC funding model.
    • Analysis of challenges specific to pediatric medical device development versus drug therapies.
    • Case study review of successful PDC-backed devices.
    • Comparative analysis of PDC funding with European pediatric device funding strategies.

    Main Results:

    • PDCs provide essential funding, expertise, and regulatory guidance to OEMs.
    • PDCs effectively address the unique hurdles in pediatric device innovation.
    • Successful examples demonstrate the tangible outcomes of PDC support.
    • The FDA's PDC grant program shows significant value, especially when compared internationally.

    Conclusions:

    • Pediatric Device Consortia are vital for advancing medical technology for children.
    • PDCs offer a comprehensive support system, overcoming significant development barriers.
    • The US PDC model provides a valuable framework for pediatric device innovation.

    More Related Videos

    Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device07:41

    Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

    Published on: July 20, 2022

    1.8K
    A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn11:27

    A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

    Published on: April 7, 2023

    6.1K

    Related Concept Videos

    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

    PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).